ImmuPharma makes solid progress with Lupuzor trial
Immupharma
2.35p
16:05 19/04/24
4.91%
0.11p
Specialist drug discovery and development company ImmuPharma updated the market on its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor on Thursday.
FTSE AIM All-Share
745.67
17:08 19/04/24
n/a
n/a
Pharmaceuticals & Biotechnology
21,247.91
17:09 19/04/24
0.54%
115.14